vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Freeport-McMoRan (FCX). Click either name above to swap in a different company.
Freeport-McMoRan is the larger business by last-quarter revenue ($5.3B vs $2.8B, roughly 1.9× Bausch Health Companies Inc.). Freeport-McMoRan runs the higher net margin — 10.7% vs -3.7%, a 14.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -10.4%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-312.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -7.9%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona. The company is the world's largest producer of molybdenum, a major copper producer and operates the world's largest gold mine, the Grasberg mine in Papua, Indonesia.
BHC vs FCX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $5.3B |
| Net Profit | $-103.0M | $565.0M |
| Gross Margin | — | 12.4% |
| Operating Margin | 17.0% | 15.4% |
| Net Margin | -3.7% | 10.7% |
| Revenue YoY | 9.3% | -10.4% |
| Net Profit YoY | -205.1% | -21.6% |
| EPS (diluted) | $-0.30 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $5.3B | ||
| Q3 25 | $2.7B | $6.8B | ||
| Q2 25 | $2.5B | $7.5B | ||
| Q1 25 | $2.3B | $5.6B | ||
| Q4 24 | $2.6B | $5.9B | ||
| Q3 24 | $2.5B | $6.7B | ||
| Q2 24 | $2.4B | $6.4B | ||
| Q1 24 | $2.2B | $6.2B |
| Q4 25 | $-103.0M | $565.0M | ||
| Q3 25 | $179.0M | $1.2B | ||
| Q2 25 | $148.0M | $1.5B | ||
| Q1 25 | $-58.0M | $793.0M | ||
| Q4 24 | $98.0M | $721.0M | ||
| Q3 24 | $-85.0M | $1.2B | ||
| Q2 24 | $10.0M | $1.3B | ||
| Q1 24 | $-64.0M | $1.2B |
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 29.2% | ||
| Q2 25 | — | 34.2% | ||
| Q1 25 | — | 24.3% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 30.0% | ||
| Q2 24 | — | 31.5% | ||
| Q1 24 | — | 28.5% |
| Q4 25 | 17.0% | 15.4% | ||
| Q3 25 | 23.1% | 28.9% | ||
| Q2 25 | 17.5% | 32.3% | ||
| Q1 25 | 12.2% | 23.4% | ||
| Q4 24 | 21.8% | 21.1% | ||
| Q3 24 | 12.7% | 29.0% | ||
| Q2 24 | 16.2% | 32.0% | ||
| Q1 24 | 13.1% | 26.3% |
| Q4 25 | -3.7% | 10.7% | ||
| Q3 25 | 6.7% | 18.3% | ||
| Q2 25 | 5.8% | 20.6% | ||
| Q1 25 | -2.6% | 14.2% | ||
| Q4 24 | 3.8% | 12.3% | ||
| Q3 24 | -3.4% | 18.5% | ||
| Q2 24 | 0.4% | 20.0% | ||
| Q1 24 | -3.0% | 18.7% |
| Q4 25 | $-0.30 | — | ||
| Q3 25 | $0.48 | $0.46 | ||
| Q2 25 | $0.40 | $0.53 | ||
| Q1 25 | $-0.16 | $0.24 | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $-0.23 | $0.36 | ||
| Q2 24 | $0.03 | $0.42 | ||
| Q1 24 | $-0.17 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $3.8B |
| Total DebtLower is stronger | $20.8B | $9.4B |
| Stockholders' EquityBook value | $-554.0M | $18.9B |
| Total Assets | $26.4B | $58.2B |
| Debt / EquityLower = less leverage | — | 0.50× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $3.8B | ||
| Q3 25 | $1.3B | $4.3B | ||
| Q2 25 | $1.7B | $4.5B | ||
| Q1 25 | $1.1B | $4.4B | ||
| Q4 24 | $1.2B | $3.9B | ||
| Q3 24 | $719.0M | $5.0B | ||
| Q2 24 | $595.0M | $5.3B | ||
| Q1 24 | $733.0M | $5.2B |
| Q4 25 | $20.8B | $9.4B | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | $9.4B | ||
| Q4 24 | $21.6B | $8.9B | ||
| Q3 24 | $21.5B | $9.7B | ||
| Q2 24 | $21.7B | $9.4B | ||
| Q1 24 | $22.1B | $9.4B |
| Q4 25 | $-554.0M | $18.9B | ||
| Q3 25 | $-565.0M | $18.7B | ||
| Q2 25 | $-764.0M | $18.2B | ||
| Q1 25 | $-1.2B | $17.7B | ||
| Q4 24 | $-1.3B | $17.6B | ||
| Q3 24 | $-1.2B | $17.5B | ||
| Q2 24 | $-1.2B | $17.4B | ||
| Q1 24 | $-1.1B | $17.0B |
| Q4 25 | $26.4B | $58.2B | ||
| Q3 25 | $26.8B | $56.8B | ||
| Q2 25 | $27.3B | $56.5B | ||
| Q1 25 | $26.4B | $56.0B | ||
| Q4 24 | $26.5B | $54.8B | ||
| Q3 24 | $26.5B | $55.4B | ||
| Q2 24 | $26.5B | $54.6B | ||
| Q1 24 | $26.9B | $54.2B |
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $693.0M |
| Free Cash FlowOCF − Capex | $403.0M | $-312.0M |
| FCF MarginFCF / Revenue | 14.4% | -5.9% |
| Capex IntensityCapex / Revenue | 3.3% | 19.1% |
| Cash ConversionOCF / Net Profit | — | 1.23× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $693.0M | ||
| Q3 25 | $405.0M | $1.7B | ||
| Q2 25 | $289.0M | $2.2B | ||
| Q1 25 | $211.0M | $1.1B | ||
| Q4 24 | $601.0M | $1.4B | ||
| Q3 24 | $405.0M | $1.9B | ||
| Q2 24 | $380.0M | $2.0B | ||
| Q1 24 | $211.0M | $1.9B |
| Q4 25 | $403.0M | $-312.0M | ||
| Q3 25 | $314.0M | $608.0M | ||
| Q2 25 | $190.0M | $934.0M | ||
| Q1 25 | $96.0M | $-114.0M | ||
| Q4 24 | $495.0M | $197.0M | ||
| Q3 24 | $334.0M | $673.0M | ||
| Q2 24 | $302.0M | $840.0M | ||
| Q1 24 | $129.0M | $642.0M |
| Q4 25 | 14.4% | -5.9% | ||
| Q3 25 | 11.7% | 8.9% | ||
| Q2 25 | 7.5% | 12.4% | ||
| Q1 25 | 4.2% | -2.0% | ||
| Q4 24 | 19.3% | 3.4% | ||
| Q3 24 | 13.3% | 10.1% | ||
| Q2 24 | 12.6% | 13.1% | ||
| Q1 24 | 6.0% | 10.3% |
| Q4 25 | 3.3% | 19.1% | ||
| Q3 25 | 3.4% | 15.5% | ||
| Q2 25 | 3.9% | 16.8% | ||
| Q1 25 | 5.1% | 21.0% | ||
| Q4 24 | 4.1% | 21.1% | ||
| Q3 24 | 2.8% | 17.9% | ||
| Q2 24 | 3.2% | 17.4% | ||
| Q1 24 | 3.8% | 20.2% |
| Q4 25 | — | 1.23× | ||
| Q3 25 | 2.26× | 1.33× | ||
| Q2 25 | 1.95× | 1.42× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | 6.13× | 1.99× | ||
| Q3 24 | — | 1.51× | ||
| Q2 24 | 38.00× | 1.53× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
FCX
| Morenci | $2.5B | 47% |
| Grasberg Segment | $964.0M | 18% |
| Copper In Concentrates | $934.0M | 18% |
| Molybdenum | $541.0M | 10% |
| Gold | $388.0M | 7% |
